Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Adlai Nortye Ltd.NASDAQ: ANL

Net Debt · Q4 FY2025 · quarter ended Dec 2025

Net debt turns positive

Q4 FY2025 net debt was $2.59M, compared with -$33.68M a year earlier.

Context

  • Net debt amounted to 7.5% of total assets at the end of Q4 FY2025, down 39.7 pp from a year earlier.
  • Net debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +107.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$2.59M— QoQ
Last fiscal yearDec 2025
$2.59M+107.7% YoY
Year agoDec 2024
-$33.68M+107.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.7%——
1 year+107.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
2.59M USD
Year-over-year change
+107.7%

Net Debt vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's Dec 2025 net debt of $2.59M is the highest of the 7 companies compared; the peer median is -$24.39M.
  • Its year-over-year change of +107.7% is the highest of 7, against a peer median of -29.9%.
  • Net debt amounts to 7.5% of total assets for ANL, versus a peer median of 18.3%.
ANL Competitors Peer median
Net Debt for ANL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANLAdlai Nortye Ltd.Dec 2025$2.59M +107.7%—7.5%
APLMApollomics, Inc.Dec 2025-$2.63M +70.1%—39.2%
NUVBNuvation Bio Inc.Jun 2026-$6.46M +96.6%—0.9%
CGENCompugen Ltd.Mar 2026-$9.5M +19.5%—6.5%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026-$39.27M -921.0%—15.5%
FHTXFoghorn Therapeutics Inc.Mar 2026-$46.92M -79.3%—21.1%
VSTMVerastem, Inc.Mar 2026-$80.08M -96.4%—35.2%
Peer median (excluding ANL) -$24.39M-29.9%—18.3%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents64.13M42.76M91.49M60.9M23.79M
Short-term Investments53.81M21.29M7.01M7K0
Net Receivables1.93M346K359K1.17M1.39M
Inventory0(3)000
Other Current Assets03000
Total Current Assets124.54M66.3M101.2M64.06M26.89M
Property, Plant & Equipment (Net)6.59M5.88M3.8M2.71M3.02M
Goodwill00000
Intangible Assets97K89K63K40K19K
Long-term Investments0024.85M4.16M4.25M
Tax Assets00000
Other Non-current Assets455K327K282K304K253K
Total Non-current Assets7.14M6.29M28.99M7.21M7.54M
Total Assets131.69M72.59M130.19M71.27M34.43M
Account Payables2.98M13.1M14.35M10.15M12.64M
Short-term Debt10.46M4.31M30.36M26.33M25.25M
Tax Payables00773K75K0
Deferred Revenue03.88M05M0
Other Current Liabilities737.99K290.11M433K(3.06M)597K
Total Current Liabilities17.5M312.65M49.67M45.36M41.63M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)005M00
Other Non-current Liabilities297.56M0000
Total Non-current Liabilities299.62M1.24M5.47M425K1.13M
Total Liabilities317.11M313.89M55.14M45.79M42.76M
Common Stock4K4K11K11K12K
Retained Earnings(209.43M)(268.22M)(373.09M)(429.32M)(464.85M)
Accumulated OCI(1M)9.53M(4.24M)(4.54M)17.25M
Other Stockholders Equity7.61M13.69M18.02M20.31M0
Minority Interest00000
Total Equity(185.43M)(241.29M)75.05M25.49M(8.32M)
Total Debt13.35M6.54M31.55M27.23M26.38M
Net Debt(50.79M)(36.21M)(59.94M)(33.68M)2.59M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.